Anxo Pharmaceutical Co., Ltd. (TPEX:6677)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Development of Western Medicine and Marketing Department	826.42M	788.71M	784.93M	721.91M	726.66M
Western Medicine Manufacturing Department	408.03M	485.87M	533.31M	491.47M	426.28M
Adjustment and Write-Off	-391.19M	-379.27M	-378.30M	-347.11M	-328.83M
Total	843.26M	895.32M	939.94M	866.27M	824.10M

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Taiwan	648.88M	621.94M	632.19M	561.86M	579.90M
Japan	940.00K	483.00K	510.00K	574.00K	19.35M
Europe	119.98M	128.96M	147.51M	136.99M	167.48M
China	57.39M	51.94M	19.27M	27.23M	32.52M
Singapore	6.74M	91.03M	139.17M	138.71M	24.37M
Others	9.34M	967.00K	1.29M	911.00K	487.00K
Total	843.26M	895.32M	939.94M	866.27M	824.10M

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 30, 2026

Data Sources Report a data error